Kadmon's Rezurock (belumosudil) Receives the US FDA's Approval for the Treatment of Chronic Graft Versus Host Disease
Shots:
- The approval is based on KD025-213 study evaluating Rezurock (200 mg- qd) aged >12 yrs. in 65 patients with cGVHD who had received 2 to 5 prior lines of systemic therapy. The anticipated PFUFA date is Aug 30- 2021
- Results: ORR (75%) through Cycle 7- day 1 treatment with CR (6%) & PR (69%); median time to 1st response (1.8mos.)- 62% of responders did not require new systemic therapy for at least 12mos. following response- m-DoR (1.9mos.)- a median time from cGVHD diagnosis was 25.3 mos.
- Rezurock (belumosudil) is the 1st approved therapy targeting ROCK2 and expected to be available in the US in Aug’21. The FDA has granted BTD & PR for Rezurock & reviewed the NDA under RTOR pilot program
Ref: kadmon | Image: LinkedIn
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com